SKYE BIOSCIENCE INC (SKYE)
US83086J2006 - Common Stock
Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on...
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on...
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity
CBeyond™ will assess nimacimab’s ability to safely induce weight loss, and will also evaluate a combination of a GLP-1 receptor agonist plus nimacimab...
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3...
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
SKYE Investors Have Opportunity to Join Skye Bioscience, Inc. Fraud Investigation with the Schall Law Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). Such investors...
Oversold Conditions For Skye Bioscience (SKYE)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). Such investors...
Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
Skye introduces collaboration with Beacon Biosignals to evaluate potential impact of Nimacimab on sleep quality and sleep apnea...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). Such investors...
Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the...
Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab
Renowned clinicians and academics bring extensive experience in obesity and metabolic medicine...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). Such investors...
Relative Strength Alert For Skye Bioscience
Skye Bioscience Appoints Dr. Karen Smith to Board of Directors
Seasoned industry veteran adds significant global biotech and biopharma experience to Skye’s Board of Directors...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). Such investors...
Skye Bioscience Added to Russell 2000® and Russell 3000® Indexes
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the...
Skye BioScience Participating in Piper Sandler Virtual Obesity Day
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). Such investors...
Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet
The company is focusing on obesity treatment after its glaucoma drug failed.
Skye Bioscience Becomes Oversold (SKYE)
Skye Bioscience to Present at Jefferies Global Healthcare Conference
Skye provides webcast link for corporate presentation...
Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
Poster presentation details screening approach allowing selection of candidate molecules applicable to dry eye disease and chronic ocular pain, with...
Skye Bioscience to Present at Upcoming Investment Conferences
SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the...
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game.
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
These three biotech stocks are leading the sector higher on upbeat news but is this as good as it gets or do they have more gas in the tank?
Skye Bioscience Uplists to The Nasdaq Global Market
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the
Skye Bioscience Announces $40 Million Private Placement Equity Financing
San Diego, California--(Newsfile Corp. - March 11, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) (the Company), a clinical stage biotechnology...
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (